Given the epidemiology of polysubstance use, patients, health professionals and regulatory bodies
should be aware that such drugs present an increased risk of slowing down alcohol metabolism, which may result in potentially toxic plasma alcohol concentrations and the related alcohol–health consequences, causing associate risk behavioral impairment along with psychosocial, legal and forensic implications